Cel-Sci Corporation (NYSEMKT:CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock. Pricing the units at $1.40 apiece for gross proceeds of $10 million. CEL-SCI Corporation (NYSEMKT:CVM) shares after opening at $1.35 moved to $1.41 on last trade day and at the end of the day closed at $1.31. Company price to sales ratio in past twelve months was calculated as 244.36 and price to cash ratio as 5.43. CEL-SCI Corporation (NYSEMKT:CVM) showed a negative weekly performance of -14.38%.
Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced yesterday the formation of a Clinical Advisory Board (CAB) to support development of the Company’s constipation-predominant irritable bowel syndrome (C-IBS) program. Synthetic Biologics Inc. (NYSEMKT:SYN) shares advanced 1.18% in last trading session and ended the day on $2.57. SYN return on equity ratio is recorded as -200.50% and its return on assets is -193.80%. Synthetic Biologics Inc. (NYSEMKT:SYN) yearly performance is 58.64%.
Mattson Technology, Inc. (NASDAQ: MTSN), a leading supplier of advanced process equipment used to manufacture semiconductors, announced that the company will host a conference call on Thursday, April 24. Mattson Technology, Inc. (NASDAQ:MTSN) shares moved down -7.86% in last trading session and was closed at $2.11, while trading in range of $2.08 – $2.37. Mattson Technology, Inc. (NASDAQ:MTSN) year to date (YTD) performance is -22.99%.
Equities researchers at Piper Jaffray assumed coverage on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating and a $4.00 price target on the stock. Piper Jaffray’s price target would indicate a potential upside of 94.17% from the stock’s previous close. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) weekly performance is -4.85%. On last trading day company shares ended up $1.96. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) distance from 50-day simple moving average (SMA50) is -8.27%. Analysts mean target price for the company is $4.69.
Leave a Reply